StockNews.AI
ZCTFF
StockNews.AI
14 days

Zero Candida Technologies Announces DTC Eligibility and to Present at OTCQB Venture Virtual Investor Conference on August 7th

1. ZCT's shares now eligible for DTC electronic clearing and settlement. 2. DTC eligibility enhances liquidity and lowers transaction costs for U.S. investors. 3. ZCT will present at the OTCQB Venture Virtual Investor Conference. 4. The company develops a device targeting Vulvo-Vaginal Candidiasis treatment. 5. Projected VVC treatment market to exceed $2B in next five years.

8m saved
Insight
Article

FAQ

Why Bullish?

DTC eligibility significantly increases liquidity, attracting more institutional investors. Historical trends show improved valuation for companies post-DTC eligibility.

How important is it?

DTC eligibility and market participation enhance investment appeal and potential share value.

Why Long Term?

The long-term visibility generated by DTC eligibility and conference presentations should result in sustained investor interest.

Related Companies

ZCTCANDABCXYZ
, /PRNewswire/ -- Zero Candida Technologies, Inc. (TSXV: ZCT) (OTCQB: ZCTFF) (FSE: 9L2) (the "Company" or "ZCT"), a FemTech medical device company revolutionizing women's health, is pleased to announce that its common shares are now eligible for Depository Trust Company ("DTC") electronic clearing and settlement services. Additionally, the Company will present live at the OTCQB Venture Virtual Investor Conference hosted by VirtualInvestorConferences.com on August 7th, 2025. Eli Ben Haroosh, Founder and CEO of ZCT, commented: "Achieving DTC eligibility represents a significant advancement in our capital markets strategy, providing enhanced liquidity and accessibility for our U.S. investors. Combined with our participation in the upcoming OTCQB Venture Virtual Investor Conference, we are positioned to reach a broader institutional and retail investor audience as we unlock value through AI-driven medical technology." DTC Eligibility Benefits DTC eligibility enables electronic clearing and settlement of Zero Candida's common shares in the United States, significantly improving trading efficiency and reducing settlement times for investors. This development is expected to enhance liquidity, reduce transaction costs, and make the Company's shares more accessible to a wider range of U.S. investors, including institutions that require DTC eligibility for investment consideration. Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors. Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings, and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors. The OTCQB Venture Market, operated by OTC Markets Group and recognized by the U.S. Securities and Exchange Commission (SEC), is a leading marketplace for early- and development-stage U.S. and international companies. The OTCQB has demonstrated its effectiveness in helping companies build shareholder value and achieve fair valuation through enhanced transparency and liquidity. To find real-time quotes and market information on Zero Candida, visit www.otcmarkets.com About Zero Candida Technologies Zero Candida Technologies, Inc. (TSXV: ZCT) (OTCQB: ZCTFF) (FSE: 9L2) is a publicly traded FemTech company pioneering innovative solutions to address unmet needs in women's health. The company is developing a tampon-like device that uses artificial intelligence and therapeutic blue light at a precise wavelength and intensity to effectively treat Candida fungus, with a proven 99.999% success rate in POC. Vulvo-Vaginal Candidiasis (VVC) affects approximately 75% of women worldwide, and recurrent cases (four or more episodes per year) are increasingly resistant to existing drug treatments, as the root cause remains poorly understood and inadequately addressed. ZCT is following a de novo regulatory pathway and is preparing for an upcoming clinical trial after successfully completing a safety trial in large animals (sheep). The Company has secured funding and partnerships with leading hospitals in Europe and Israel, and is expanding its global patent portfolio, with applications filed in the United States, Brazil, and Europe, and a full patent already granted in South Africa. With the VVC treatment market projected to exceed USD $2B in the next five years, ZCT is combining hybrid medicine and technology-based diagnostics to improve access to underserved populations and bring gynecology into the 21st century. To learn more, visit www.zero-candida.com Forward-Looking Statements This news release includes certain statements and information that constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, are forward-looking statements. The Company provides no assurance that forward-looking statements and information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements or information. Accordingly, readers should not place undue reliance on forward-looking statements or information. The Company does not undertake to update any forward-looking statements, other than as required by law. More detailed information about potential factors that could affect financial results is included in the documents filed from time to time with the Canadian securities regulatory authorities by Zero Candida. Readers are cautioned not to place undue reliance on forward-looking statements. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release. Company Contacts:Eli Ben HarooshCEO & Founder[email protected] Victoria Gamble[email protected](647) 874 3767 Logo: https://mma.prnewswire.com/media/2420533/5146953/ZERO_CANDIDA_Logo.jpg SOURCE Zero Candida WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News